Derma Sciences Cmn (DSCI) 4.55 $DSCI Derma Sciences

New Post Public Reply Private Reply Replies (0) Message Board

Sep 19, 2016 at 9:06 AM

Derma Sciences Cmn (DSCI) 4.55 $DSCI

Derma Sciences Completes the Sale of Its First Aid Products Division
BusinessWire - Thu Sep 01, 3:05PM CDT
Derma Sciences, Inc. (Nasdaq

SCI), a tissue regeneration company focused on advanced wound and burn care, announces the completion of the sale of its First Aid Division (FAD) to Dukal Corporation for $12.4 million, including inventory. The proposed sale was first announced on July 27, 2016.
DSCI: 4.55 (-0.03)

Henry Schein Poised on Strategic Buyouts, Pricing Hurts
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 6:23AM CDT
On Sep 1, we issued an updated research report on Henry Schein, Inc. (HSIC).
DSCI: 4.55 (-0.03), ALGN: 93.84 (+0.91), HSIC: 164.10 (+1.33), MMSI: 24.14 (-0.29)

Others Overlooked Derma Sciences (DSCI), Should You Buy It Now?
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:50AM CDT
Derma Sciences (DSCI) is well positioned for a solid gain, but has been overlooked by investors lately
DSCI: 4.55 (-0.03)

LabCorp's Takeover of Sequenom Wins Antitrust Clearance
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 4:26PM CDT
LabCorp (LH) recently got the antitrust review clearance for its previously announced acquisition of Sequenom.
DSCI: 4.55 (-0.03), SQNM: 2.39 (-0.01), ALGN: 93.84 (+0.91), LH: 135.38 (+0.70)

Derma Sciences Receives Reimbursement Coding for New MEDIHONEY(R) Hydrogel Dressings
BusinessWire - Thu Aug 25, 6:30AM CDT
Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the launch of new, MEDIHONEY(R) Hydrogel Sheet Dressings and the receipt of Healthcare Common Procedural Coding System (HCPCS) codes awarded on August 19, 2016 by the Centers for Medicare and Medicaid Services (CMS).
DSCI: 4.55 (-0.03)

Derma Sciences' AMNIOEXCEL(R) Now Eligible for Reimbursement by Medicare Administrative Contractor NGS
BusinessWire - Wed Aug 24, 3:05PM CDT
Derma Sciences, Inc. (Nasdaq

SCI), a tissue regeneration company focused on advanced wound and burn care, announces that National Government Services (NGS), a Medicare Administrative Contractor (MAC) for Part B serving States primarily in the Northeast and Midwest, and National MAC for Jurisdiction 6, has retired its local coverage determination (LCD) for cellular or tissue-based products (CTPs) effective September 1, 2016. As a result, the Company's AMNIOEXCEL(R) Amniotic Allograft Membrane (AMNIOEXCEL(R)) will be considered for coverage with appropriate documentation of medical necessity as a second-line therapy following standard wound care treatment.
DSCI: 4.55 (-0.03)

LabCorp Q2 Results Strong, Sequenom Buyout Raises Hope
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 10:16AM CDT
On Aug 18, 2016, we issued an updated research report on LabCorp (LH), a leading independent clinical laboratory company.
DSCI: 4.55 (-0.03), ALGN: 93.84 (+0.91), LH: 135.38 (+0.70), ATRS: 1.43 (+0.03)

Derma Sciences Names Russell Olsen President of Advanced Wound Care
BusinessWire - Thu Aug 18, 6:30AM CDT
Derma Sciences, Inc. (Nasdaq

SCI), a tissue regeneration company focused on advanced wound and burn care, announces the appointment of Russell Olsen as President of Advanced Wound Care. Mr. Olsen is President and Chief Executive Officer of BioD, LLC, a regenerative medicine products company Derma Sciences acquired earlier this month.
DSCI: 4.55 (-0.03)

New Strong Buy Stocks for August 11th
Tirthankar Chakraborty - Zacks Investment Research - Thu Aug 11, 6:17AM CDT
New Strong Buy Stocks for August 11th
DSCI: 4.55 (-0.03), DISCK: 23.61 (-0.09), DGI: 24.59 (-0.66), BEAT: 18.44 (-0.75), CVCY: 15.80 (+0.07)

Derma Sciences Reports 2016 Second Quarter Financial Results
BusinessWire - Tue Aug 09, 6:30AM CDT
--2016 financial guidance revised to include recent transactions
DSCI: 4.55 (-0.03)

Derma Sciences to Hold Second Quarter Financial Results Conference Call on August 9th
BusinessWire - Wed Aug 03, 8:13AM CDT
Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on August 9, 2016 to discuss the financial results for the second quarter of 2016. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
DSCI: 4.55 (-0.03)

Derma Sciences to Acquire BioD, Solidify Its Leadership Position in Advanced Wound Care and Regenerative Products
BusinessWire - Thu Jul 28, 6:30AM CDT
--Will add 235 independent sales representatives and seven direct sales representatives with no call-point or customer overlap
DSCI: 4.55 (-0.03)

Why Derma Sciences (DSCI) Could Be Positioned for a Surge
Zacks Equity Research - Zacks Investment Research - Tue May 24, 7:35AM CDT
Derma Sciences (DSCI) has a decent short-term momentum and it is seeing solid activity on the earnings estimate revision front as well.
DSCI: 4.55 (-0.03)

Can The Uptrend Continue for Derma Sciences (DSCI)?
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:56AM CDT
Investors certainly have to be happy with Derma Sciences Inc (DSCI) and its short term performance
DSCI: 4.55 (-0.03)

Derma Sciences reports 1Q loss
Automated Insights - Wed May 11, 6:37AM CDT
PRINCETON, N.J. (AP) _ Derma Sciences Inc. (DSCI) on Wednesday reported a loss of $1.8 million in its first quarter.
DSCI: 4.55 (-0.03)

Derma Sciences Reports 2016 First Quarter Financial Results
BusinessWire - Wed May 11, 6:30AM CDT
--Conference call begins at 11:00 a.m. Eastern Time today
DSCI: 4.55 (-0.03)

Research and Markets -- European Advanced Wound Care Market Analysis - Trends, Technologies & Opportunities Report 2016-2021 - Key Vendors: Shire, Organogenesis, Derma Sciences
PR Newswire Europe - Fri May 06, 2:11PM CDT
DUBLIN, May 6, 2016 /PRNewswire/ --
DSCI: 4.55 (-0.03)

Derma Sciences to Hold First Quarter Financial Results Conference Call on May 11th
BusinessWire - Fri May 06, 1:31PM CDT
Derma Sciences, Inc. (Nasdaq

SCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on May 11, 2016 to discuss the financial results for the first quarter of 2016. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
DSCI: 4.55 (-0.03)

Derma Sciences Announces AMNIOEXCEL(R) Is Now Eligible for Reimbursement by Medicare Administrative Contractor CGS
BusinessWire - Wed Apr 27, 6:30AM CDT
Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that CGS Administrators, LLC (CGS), a Medicare Administrative Contractor (MAC) for Parts A and B serving Kentucky and Ohio, has updated its local coverage determination (LCD) for cellular or tissue-based products (CTPs) of the lower extremity. As a result, the Company's AMNIOEXCEL(R) Amniotic Allograft Membrane (AMNIOEXCEL(R)) will be considered for reimbursement coverage with appropriate documentation of medical necessity for the treatment of chronic wounds of the lower extremity, including both diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Coverage is effective as of April 1, 2016. CGS is the sixth MAC to issue local coverage determinations for AMNIOEXCEL(R).
DSCI: 4.55 (-0.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...